With New Huntington’s Gene Therapy Data, uniQure Hopes for Faster Path With FDA

Posted
A uniQure gene therapy for Huntington’s disease has interim clinical data showing an 80% slowing of disease progression. An accelerated approval pathway is one of the topics the company wants to discuss with the FDA. The post With New Huntington’s Gene Therapy Data, uniQure Hopes for Faster Path With FDA appeared first on MedCity News.

Continue reading at MedCity News »

BioPharma, Daily, Pharma, Amsterdam, biopharma nl, Clinical Trials, FDA, gene therapy, Huntington's disease, uniQure